Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
University of Ulsan College of Medicine, Seoul, Republic of Korea.
Sci Rep. 2021 Apr 15;11(1):8312. doi: 10.1038/s41598-021-87747-1.
The clinical characteristics of lung cancer in patients with idiopathic pulmonary fibrosis (IPF) differ from those of lung cancer in patients without IPF. Thus, we aimed to evaluate the impact of IPF on the clinical course of patients with lung cancer. Clinical data of IPF patients with lung cancer (n = 122) were compared with those of patients with lung cancer without IPF (n = 488) matched by age, sex, histopathology, stage, and date of diagnosis of lung cancer. The median follow-up period after diagnosis of lung cancer was 16 months. Among patients with IPF, the mean age was 68 years, 95.9% were male, 93.2% were ever-smokers, and squamous cell carcinoma was the most common cancer type (48.4%). The IPF group had poorer lung function and lower lobe predominance of lung cancer than the no-IPF group. The IPF group showed a poorer prognosis than the no-IPF group (5-year survival rate: 14.5% vs. 30.1%, respectively; P < 0.001), even after adjusting for lung function and regardless of the treatment method. Among patients with IPF, 16.8% experienced acute exacerbation within 1 month after treatment of lung cancer. The treatment outcome of patients with lung cancer and IPF was generally unfavorable, and acute exacerbation triggered by treatment frequently occurred.
特发性肺纤维化（IPF）患者肺癌的临床特征与非 IPF 患者肺癌不同。因此，我们旨在评估 IPF 对肺癌患者临床病程的影响。比较了 122 例 IPF 合并肺癌患者（IPF 组）与 488 例年龄、性别、组织病理学、分期和肺癌诊断日期匹配的非 IPF 肺癌患者（非 IPF 组）的临床数据。肺癌诊断后中位随访时间为 16 个月。在 IPF 组中，患者的平均年龄为 68 岁，95.9%为男性，93.2%为吸烟者，最常见的癌症类型为鳞状细胞癌（48.4%）。与非 IPF 组相比，IPF 组的肺功能较差，下叶肺癌更为常见。与非 IPF 组相比，IPF 组的预后较差（5 年生存率分别为 14.5%和 30.1%；P<0.001），即使在调整了肺功能后，且不论治疗方法如何。在 IPF 患者中，16.8%在肺癌治疗后 1 个月内经历急性加重。IPF 合并肺癌患者的治疗结果通常不佳，且治疗常引发急性加重。
